Belinda Cowling
#74,738
Most Influential Person Now
French medical researcher
Belinda Cowling's AcademicInfluence.com Rankings
Belinda Cowlinglaw Degrees
Law
#3516
World Rank
#4455
Historical Rank
Common Law
#262
World Rank
#285
Historical Rank
International Law
#2004
World Rank
#2383
Historical Rank
Download Badge
Law
Belinda Cowling's Degrees
- PhD Medical Research Université Paris Cité
- Masters Biomedical Sciences Université Paris Cité
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Belinda Cowling Influential?
(Suggest an Edit or Addition)According to Wikipedia, Belinda S. Cowling is a French medical researcher and cofounder and scientific advisor of the biotech firm Dynacure, which was founded in 2016. She became Head of Research in 2018, responsible for the company’s R&D strategy, and leading Dynacure’s research programs in centronuclear myopathy and other disease domains. As Dynacure's Chief Scientific Officer, her focus is on translational research and drug-candidate development. In 2019, she was awarded the Irène Joliot-Curie Prize in the category: Women, Research and Enterprise.
Belinda Cowling's Published Works
Published Works
- Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy. (2008) (136)
- Four and a Half LIM Protein 1 Binds Myosin-binding Protein C and Regulates Myosin Filament Formation and Sarcomere Assembly* (2006) (118)
- The caveolin–cavin system plays a conserved and critical role in mechanoprotection of skeletal muscle (2015) (114)
- Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies (2011) (114)
- Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy (2008) (113)
- Amphiphysin 2 (BIN1) in physiology and diseases (2014) (110)
- Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. (2014) (103)
- Reciprocal Effects on Neurocognitive and Metabolic Phenotypes in Mouse Models of 16p11.2 Deletion and Duplication Syndromes (2016) (97)
- Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness. (2011) (87)
- Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: A comprehensive review of the clinical, histological and pathological features (2011) (78)
- Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice (2017) (68)
- Defective Membrane Remodeling in Neuromuscular Diseases: Insights from Animal Models (2012) (60)
- Myotubularin and PtdIns3P remodel the sarcoplasmic reticulum in muscle in vivo (2013) (58)
- Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. (2013) (58)
- Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation (2017) (56)
- FHL3 binds MyoD and negatively regulates myotube formation (2007) (55)
- Altered Splicing of the BIN1 Muscle-Specific Exon in Humans and Dogs with Highly Progressive Centronuclear Myopathy (2013) (49)
- Phosphatase-Dead Myotubularin Ameliorates X-Linked Centronuclear Myopathy Phenotypes in Mice (2012) (49)
- Implanted myoblast survival is dependent on the degree of vascularization in a novel delayed implantation/prevascularization tissue engineering model. (2010) (43)
- WANTED - Dead or alive: Myotubularins, a large disease-associated protein family. (2017) (40)
- Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy (2018) (38)
- Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice. (2018) (32)
- Centronuclear myopathies under attack: A plethora of therapeutic targets (2018) (25)
- SLIMMER (FHL1B/KyoT3) Interacts with the Proapoptotic Protein Siva-1 (CD27BP) and Delays Skeletal Myoblast Apoptosis* (2009) (21)
- Amphiphysin 2 modulation rescues myotubular myopathy and prevents focal adhesion defects in mice (2019) (21)
- Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy (2018) (21)
- Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes (2019) (19)
- P.251 Expression of the neuropathy-associated MTMR2 gene rescues MTM1-associated myopathy (2017) (17)
- Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy (2021) (16)
- Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. (2014) (14)
- Translational medicine in neuromuscular disorders: from academia to industry (2019) (13)
- Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients (2020) (12)
- Different in vivo impact of Dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or Centronuclear Myopathy. (2019) (12)
- Correction: Altered Splicing of the BIN1 Muscle-Specific Exon in Humans and Dogs with Highly Progressive Centronuclear Myopathy (2013) (11)
- Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin (2020) (10)
- Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes. (2021) (9)
- Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances (2021) (8)
- Differential physiological roles for BIN1 isoforms in skeletal muscle development, function and regeneration (2020) (8)
- BIN1 modulation in vivo rescues dynamin-related myopathy (2022) (6)
- rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy (2020) (5)
- Natural history study and statistical modeling of disease progression in a preclinical model of myotubular myopathy (2022) (3)
- Differential physiological role of BIN1 isoforms in skeletal muscle development, function and regeneration (2018) (3)
- Differential physiological role of BIN1 isoforms in skeletal muscle development, function and regeneration. (2020) (3)
- P1.35 Amphiphysin 2 (BIN1) and triad defects in several forms of centronuclear myopathies (2010) (2)
- Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy (2022) (2)
- An integrated modelling methodology for estimating global incidence and prevalence of hereditary spastic paraplegia subtypes SPG4, SPG7, SPG11, and SPG15 (2022) (2)
- T.O.14 ASO-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice (2016) (1)
- [Decreasing dynamin 2 to rescue myotubular myopathy]. (2014) (1)
- Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy (2018) (0)
- G.O.2 Proteomic identification of the LIM domain protein FHL1 as the gene-product mutated in reducing body myopathy (2008) (0)
- G.O.21 Reducing dynamin 2 rescues a severe congenital myopathy in mice (2015) (0)
- Regulation of the transcriptional coactivator FHL2 during cancer progression, a mechanism for androgen receptor activation in castrate resistant prostate cancer (2017) (0)
- Proteomic identification of the LIM domain protein FHL1 as the gene-product mutated in reducing body myopathy (2009) (0)
- Reducing Dynamin 2 Rescues a Severe Congenital Myopathy in Mice (2016) (0)
- TH.O.19 Tamoxifen increases survival, improves motor function and reduces levels of BIN1 and DNM2 in a mouse model of X-linked centronuclear (myotubular) myopathy (2017) (0)
- G.O.22 Reducing dynamin 2 rescues centronuclear myopathy (2014) (0)
- rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy (2020) (0)
- Phenotypic Spectrum of DNM2-Related Centronuclear Myopathy (2022) (0)
- Identification of FHL 1 as a therapeutic target for Duchenne muscular dystrophy (2014) (0)
- O.02 The phenotypic spectrum of DNM2-related centronuclear myopathy (2022) (0)
- P.262 Antisense oligonucleotide-mediated Dnm2 knockdown delays myotubular myopathy in mice after a single injection (2017) (0)
- CONGENITAL MYOPATHIES (CNM) P.143Myostatin as a novel blood based biomarker for antisense oligonucleotide-mediated Dnm2 knockdown to treat myotubular myopathy in mice (2018) (0)
- CONGENITAL MYOPATHIES – CENTRONUCLEAR MYOPATHIES EP.30 Statistical modelling of disease progression in a preclinical model of myotubular myopathy (2021) (0)
- G.P.310 Late-onset mild myopathy with protein aggregates in two transgenic mouse models of FHL1 (2015) (0)
- Amphiphysin 2 (BIN1) in physiology and diseases (2014) (0)
- C.P.10 Phosphatase inactive myotubularin rescues X-linked centronuclear (myotubular) myopathy phenotypes in mice (2012) (0)
- Dynamin 2 inhibitor for the treatment of myopathies centronucleares (2014) (0)
- CONGENITAL MYOPATHIES (CNM) P.144Targeting dynamin 2 rescues the three main forms of centronuclear myopathies (2018) (0)
- G.P.12.11 In vivo manipulation of skeletal muscle to characterize the mechanisms underlying centronuclear myopathies (2009) (0)
- P.104Skeletal muscle reduction of Dnm2 with antisense oligonucleotides in myotubular myopathy (2019) (0)
- CONGENITAL MYOPATHIES – CENTRONUCLEAR MYOPATHIES EP.28 ASO-mediated Dnm2 knockdown ameliorates the centronuclear myopathy phenotype of Dnm2RW/+ mice in a dose-dependent manner after disease onset (2021) (0)
- T.P.34 FHL1 reduces muscle degeneration in dystrophin-deficient mdx mice through the sarcolemmal recruitment of utrophin (2012) (0)
- P.411 Repurposing tamoxifen for severe myopathies: from preclinical evaluation in animal models to clinical trials in patients (2017) (0)
- P.121 Dnm2 reduction combined with dystrophin re-expression ameliorates the myopathic phenotype observed in the D2-mdx model of Duchenne muscular dystrophy (2022) (0)
- C.P.7 Dynamin 2 in skeletal muscle development and diseases (2012) (0)
This paper list is powered by the following services:
Other Resources About Belinda Cowling
What Schools Are Affiliated With Belinda Cowling?
Belinda Cowling is affiliated with the following schools: